Citius Oncology
Cranford
About Citius Oncology
Citius Oncology is a biopharmaceutical company that develops and commercializes oncology therapies. The company specializes in targeted therapies for cancer treatment, with a focus on immune-based approaches. The company recently gained FDA approval for LYMPHIR™, a therapy for relapsed or refractory cutaneous T-cell lymphoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $36.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:CTOR
- Website: citiusonc.comoverviewdefault.aspx
- Phone: +1 908-967-6677
Industries & Categories
Medical, Oncology, Pharmaceutical
Canonical: https://fsome.com/organization/citius-oncology-33035 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.